Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406260 · ClinicalTrials.gov registry record · Phase 1
A Study of Lasmiditan in Healthy Elderly Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03406260 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 36 participants.
The verdict
NCT03406260, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purposes of this study are to evaluate the effect of lasmiditan on blood pressure, as well as to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it in healthy elderly participants. The tolerability of the study drug will also be evaluated. Information about any side effects that may occur will also be collected. This study will take about 11 days, not including screening. Screening is required within 28 days prior to the start of the study.
Interventions
- DRUG Placebo
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-01-25 |
| Est. Completion | 2018-04-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03406260
The ClinicalTrials.gov registry entry for NCT03406260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03406260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03406260 about?
NCT03406260 is a clinical study titled "A Study of Lasmiditan in Healthy Elderly Participants". The purposes of this study are to evaluate the effect of lasmiditan on blood pressure, as well as to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it in healthy elderly participants. The tolerability of the study drug will also be evalu...
What is the current status of trial NCT03406260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-01-25. Estimated completion is 2018-04-13.
What interventions are being tested in trial NCT03406260?
The interventions under investigation include: Placebo (DRUG), Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT03406260?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.